Palisade Bio, Inc. (PALI), a biopharmaceutical company specializing in the advancement of therapies for acute and chronic gastrointestinal (GI) complications, has announced the appointment of J.D. Finley as its Chief Executive Officer (CEO), effective immediately. Mr. Finley, who has been serving as interim CEO since October 2022, has proven his exceptional leadership and operational expertise during a challenging transitional phase for the company.

‍

Strong Leadership During Transition

Throughout his tenure as interim CEO, J.D. Finley has showcased his remarkable leadership skills, steering Palisade Bio through a demanding period of change. Under his guidance, the company has achieved notable progress in advancing the clinical development of LB1148, a revolutionary treatment for acute and chronic GI complications. Palisade Bio's Board of Directors commends Mr. Finley's contributions and expresses confidence in his ability to lead the company to new heights.

‍

Official Appointment and Recognition

In light of J.D. Finley's outstanding performance, Palisade Bio is proud to officially name him as the CEO. The announcement was met with enthusiasm from James R. Neal, Chairman of the Palisade Bio Board of Directors, who acknowledged the strength of the company under Finley's leadership. Neal expressed his satisfaction with the progress made and highlighted the positive impact Finley has had on Palisade Bio.